CAS Number191217-81-9
Synonyms2,6-Benzothiazolediamine, 4,5,6,7-tetrahydro-N-propyl-, (6S)-, hydrochloride, hydrate (1:2:1); (6S)-N-Propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine dihydrochloride hydrate; (S)-2-Amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole Dihydrochloride Monohydrate; Pramipexole dihydrochloride; Pramipexole dihydroch; pramipexole 2hcl monohydrate; (S)-2-amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole dihydrochloride PPX dihydrochloride; Pramipexole Dihydrochloride Monohydrate; Pramipexole
Molecular FormulaC10H21Cl2N3OS
Molecular Weight302.26
Purity98%%
Boiling Point378ºC at 760 mmHg
Melting Point290 °C(dec.)
AppearanceWhite to off-white crystalline powder
Symbol
Signal WordWarning
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 191217-81-9 |
| Catalog No. | 2A-9059709 |
| Chinese Name | 盐酸普拉克索一水合物 |
| Synonyms | 2,6-Benzothiazolediamine, 4,5,6,7-tetrahydro-N-propyl-, (6S)-, hydrochloride, hydrate (1:2:1); (6S)-N-Propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine dihydrochloride hydrate; (S)-2-Amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole Dihydrochloride Monohydrate; Pramipexole dihydrochloride; Pramipexole dihydroch; pramipexole 2hcl monohydrate; (S)-2-amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole dihydrochloride PPX dihydrochloride; Pramipexole Dihydrochloride Monohydrate; Pramipexole |
| Molecular Formula | C10H21Cl2N3OS |
| Molecular Weight | 302.26 |
| Purity | 98% |
| Boiling Point | 378ºC at 760 mmHg |
| Melting Point | 290 °C(dec.) |
| Appearance | White to off-white crystalline powder |
| Water Solubility | Freely soluble in water, soluble in methanol, spar |
| Storage Condition | 2-8°C |
| Application | Pramipexole dihydrochloride hydrate is a selective D2 dopamine receptor agonist, with Ki values of 2.2 nM, 3.9 nM, 0.5 nM, and 1.3 nM for D2 receptor, D2, D3, and D4 subtype receptors, respectively. |
| HTC | 2934999090 |
| SMILES | [s]1c2c(nc1N)CC[C@@H](C2)NCCC.[Cl-].[Cl-].O.[H+].[H+] |
| InChI | 1S/C10H17N3S.2ClH.H2O/c1-2-5-12-7-3-4-8-9(6-7)14-10(11)13-8;;;/h7,12H,2-6H2,1H3,(H2,11,13);2*1H;1H2/t7-;;;/m0.../s1 |
| InChI Key | APVQOOKHDZVJEX-QTPLPEIMSA-N |
| NACRES Code | NA.24 |
| UNSPSC | 41116107 |
| Hazard Symbols | transportation |
| MSDS | msds/59709_1_191217_81_9.pdf |
| Bioactivity | Pramipexole dihydrochloride hydrate is a selective dopamine D2-type receptor agonist, with Kis of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole dihydrochloride hydrate can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS). Pramipexole dihydrochloride hydrate can cross the blood-brain barrier (BBB)[1][2][3]. Related Catalog Signaling Pathways >> GPCR/G Protein >> Dopamine Receptor Signaling Pathways >> Neuronal Signaling >> Dopamine Receptor Research Areas >> Neurological Disease Target D2 Receptor:3.9 nM (Ki) D3 Receptor:0.5 nM (Ki) D4 Receptor:1.3 nM (Ki) D2-type receptors:2.2 nM (Ki) In Vitro Pramipexole dihydrochloride hydrate (0.01-10 μM; 72 hours) produces dose-dependent increases of dendritic arborization and soma size[3]. Pramipexole dihydrochloride hydrate attenuates levodopa-induced toxicity in mesencephalic cultures, suggests that pramipexole may be cytoprotective to dopamine neurons in tissue culture[4]. In Vivo Pramipexole dihydrochloride hydrate (0.25-1 mg/kg; i.p.) significantly reduces the infarction volume in animals[5]. Pramipexole dihydrochloride hydrate improves neurological recovery[5]. Pramipexole dihydrochloride hydrate prevents ischemic cell death via mitochondrial pathways in ischemic stroke[5]. Animal Model: Male Wistar rats weighing 250-300 g (16-18 weeks old)[5] Dosage: 0.25 mg/kg, 1 mg/kg Administration: Intraperitoneal injection, at 1 hour, 6 hours, 12 hours, 18 hours post-occlusion Result: Decreased infarction volume as compared to tMCAO (transient middle cerebral artery occlusion)-only animals. References [1]. Kvernmo, T., et al. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther, 2006. 28(8): p. 1065-78. [2]. Takashi Okura, et al. Blood-brain barrier transport of pramipexole, a dopamine D2 agonist. Life Sci. 2007 Apr 3;80(17):1564-71. [3]. Ginetta Collo, et al. Ropinirole and Pramipexole Promote Structural Plasticity in Human iPSC-Derived Dopaminergic Neurons via BDNF and mTOR Signaling. Neural Plast. 2018; 2018: 4196961. [4]. P M Carvey, et al. Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole. J Neural Transm (Vienna). 1997;104(2-3):209-28. [5]. Syed Suhail Andrabi, et al. Pramipexole prevents ischemic cell death via mitochondrial pathways in ischemic stroke. Dis Model Mech. 2019 Aug 1; 12(8): dmm033860. Chemical & Physical Properties Boiling Point 378ºC at 760 mmHg Melting Point 290 °C(dec.) Molecular Formula C10H21Cl2N3OS Molecular Weight 302.264 Flash Point 182.4ºC Exact Mass 301.078247 PSA 88.41000 LogP 4.09400 Vapour Pressure 9.93E-11mmHg at 25°C InChIKey APVQOOKHDZVJEX-QTPLPEIMSA-N SMILES CCCNC1CCc2nc(N)sc2C1.Cl.Cl.O Storage condition 2-8°C Water Solubility Freely soluble in water, soluble in methanol, sparingly soluble or slightly soluble in ethanol (96 per cent), practically insoluble in methylene chloride. |
| Use of | Pramipexole dihydrochloride hydrate is a selective dopamine D2-type receptor agonist, with Kis of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole dihydrochloride hydrate can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS). Pramipexole dihydrochloride hydrate can cross the blood-brain barrier (BBB)[1][2][3]. Properties Name pramipexole hydrochloride Synonym More Synonyms Pramipexole dihydrochloride hydrate Biological Activity Description Pramipexole dihydrochloride hydrate is a selective dopamine D2-type receptor agonist, with Kis of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole dihydrochloride hydrate can be used for the research of Parkinson's disease (PD) and restless legs syndrome (RLS). Pramipexole dihydrochloride hydrate can cross the blood-brain barrier (BBB)[1][2][3]. Related Catalog Signaling Pathways >> GPCR/G Protein >> Dopamine Receptor Signaling Pathways >> Neuronal Signaling >> Dopamine Receptor Research Areas >> Neurological Disease D2 Receptor:3.9 nM (Ki) D3 Receptor:0.5 nM (Ki) D4 Receptor:1.3 nM (Ki) D2-type receptors:2.2 nM (Ki) In Vitro Pramipexole dihydrochloride hydrate (0.01-10 μM; 72 hours) produces dose-dependent increases of dendritic arborization and soma size[3]. Pramipexole dihydrochloride hydrate attenuates levodopa-induced toxicity in mesencephalic cultures, suggests that pramipexole may be cytoprotective to dopamine neurons in tissue culture[4]. References [1]. Kvernmo, T., et al. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther, 2006. 28(8): p. 1065-78. [2]. Takashi Okura, et al. Blood-brain barrier transport of pramipexole, a dopamine D2 agonist. Life Sci. 2007 Apr 3;80(17):1564-71. [3]. Ginetta Collo, et al. Ropinirole and Pramipexole Promote Structural Plasticity in Human iPSC-Derived Dopaminergic Neurons via BDNF and mTOR Signaling. Neural Plast. 2018; 2018: 4196961. [4]. P M Carvey, et al. Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole. J Neural Transm (Vienna). 1997;104(2-3):209-28. [5]. Syed Suhail Andrabi, et al. Pramipexole prevents ischemic cell death via mitochondrial pathways in ischemic stroke. Dis Model Mech. 2019 Aug 1; 12(8): dmm033860. Chemical & Physical Properties Exact Mass 301.078247 PSA 88.41000 LogP 4.09400 InChIKey APVQOOKHDZVJEX-QTPLPEIMSA-N Water Solubility Freely soluble in water, soluble in methanol, sparingly soluble or slightly soluble in ethanol (96 per cent), practically insoluble in methylene chloride. |
| Tax Rebate | 13.0% |
| Supervision | None. MFN tariff: 6.5%. Ordinary tariff: 20.0% |
| Transport Info | Product name: Purity: 98.0% |
| MSDS Transport Info | Module 14. Shipping information 14.1 UN dangerous goods number European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.2 Names specified by the United Nations (UN) European Land Transport Dangerous Regulations: Non-dangerous goods IMDG Code: Non-dangerous goods International air transport dangerous goods regulations: non-dangerous goods 14.3 Transport hazard categories European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.4 Package group European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.5 Environmental hazards European Land Transport Dangerous Regulations: No International Maritime Transport Dangerous Regulations Maritime Pollutants: No International Air Transport Risk Regulations: No 14.6 Special reminder to users No data available See reverse side of invoice or packing slip. |
| Related Products in API & Advanced Intermediates | ||
|---|---|---|
| Pemetrexed disodium | 15039-23-8 | 2A-9059634 |
| Codeine | 76-57-3 | 2A-9059636 |
| Erlotinib hydrochloride | 183319-69-9 | 2A-9059637 |
| Moxifloxacin | 151096-09-2 | 2A-9059655 |
| Acyclovir, Monophosphate | 66341-16-0 | 2A-9059678 |
| Amikacin sulfate salt | 149022-22-0 | 2A-9059760 |
| 6ALPHA-HYDROXYESTRADIOL | 1229-24-9 | 2A-9059890 |
| Capecitabine intermediate | 161599-46-8 | 2A-9059921 |
| Imatinib intermediate | 152460-10-1 | 2A-9059923 |
| 17a-Methyl-1-Testosterone | 58-18-14 | 2A-9059929 |
| Browse all API & Advanced Intermediates products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS